Alogliptin

Drug Profile

Alogliptin

Alternative Names: Alogliptin benzoate; NESINA; Nesina; SYR-322; TAK-322; Vipidia

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Syrrx Inc
  • Developer Takeda
  • Class Antihyperglycaemics; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In adolescents, In children) in USA (PO, Tablet)
  • 11 Sep 2017 Adverse events data from a phase III trial in Type 2 diabetes mellitus presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD-2017)
  • 17 Aug 2017 Alogliptin market licensed to Hikma Pharmaceuticals in Middle East and North Africa, excluding Egypt
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top